What is the problem? Skin cancers are common and the number of people who are developing them is increasing. They are usually split into two groups: melanomas are less common but more serious and keratinocyte skin cancers are more common but less serious. Most need to be cut out. Keratinocyte skin cancers on the leg often cannot be closed with stitches and the wounds are left open to heal by themselves (known as secondary intention wound healing). When left open, they ...

GO TO STUDY

Allogeneic hematopoietic cell transplantation (alloHCT) is a well-established therapy for different lifethreatening hematologic malignancies. The use of alloHCT is constantly increasing, with nearly 20 000 transplantations reported to the European Society for Blood and Marrow Transplantation (EBMT) per year. However, this treatment is limited by high morbidity and mortality, mainly related to relapse, infection, graft-versus-host disease (GvHD), and conditioning-related toxicity. Therefore, overall survival (OS) and GvHD-free, relapse-free survival (GRFS) after alloHCT, remain low, around 60% and 30% at one year. Over ...

GO TO STUDY

Although the optimal treatment strategy in oesophageal (food pipe) cancer has been the subject of research for several decades, overall outcomes are very poor, with a 5-year survival of 15%. In the UK there are 9100 new cases of oesophago-gastric cancer diagnosed and approximately 7925 deaths every year (Cancer Research UK Oct 2019). Oesophageal cancer is a strategic priority for CRUK and a serious health problem world-wide. Pre-surgery treatment consists of chemotherapy or chemoradiation, but the optimal treatment is unknown. ...

GO TO STUDY

There is a paucity of data on the aetiology of myeloproliferative neoplasms (MPNs). The research group will conduct a UK wide case-control study of 560 patients with classic MPNs and up to 560 non-blood relative or friend controls to investigate the causes (aetiology) of MPNs and to evaluate quality of life2 (QoL). DNA and RNA samples from MPN patients and controls who participate in the case-control study will be collected and retained to evaluate gene-environment interactions upon receipt ...

GO TO STUDY

This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC therapy on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA). Approximately 300 eligible participants will be randomized in a 1:1 ratio, respectively, to the following treatment groups: • Obicetrapib 10 mg + ezetimibe 10 ...

GO TO STUDY

Peripheral artery disease (PAD) is a reduction of blood flow in the legs due to the narrowing or blockage of arteries. The prevalence of vascular calcification in patients with PAD hinders the outcome of endovascular treatments due to increased stiffness of the vessel wall. Treatment failure is especially high in patients with chronic limb-threatening ischemia (CLTI), the most advanced type of PAD, characterized by rest pain and tissue loss. These patients are at a high risk of limb amputation and ...

GO TO STUDY

The MANTRA trial is an open label, non-blinded, multicentre non-inferiority RCT with an internal pilot comparing the safety and effectiveness of three different surgical prophylaxis antibiotic regimens following surgery for mandible fractures. This is a multicentre trial in secondary care, involving multiple NHS OMFS units treating mandible fractures. We aim to set-up >25 sites over a 3-year trial period. We have provisional participation agreement with >50 sites and written commitment from the only UK specialist association (BAOMS) to promote, support ...

GO TO STUDY

This is a multicenter, open-label, active control extension study to assess the long-term safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. To be eligible for participation in this study, participants must have completed a designated Parent study. Qualification for this open-label extension (OLE) study will be specified in the Parent study Protocol. Participants who discontinue treatment early or discontinue from the Parent study are not eligible for this OLE study AT-1501-K209. Prospective participants ...

GO TO STUDY

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery.

GO TO STUDY

This is a Real World multi-country, retrospective, non-interventional study to describe the Real World treatment outcomes of patients with Smoldering Multiple Myeloma and compare them according to different high-risk definitions. Participants in this non-interventional study would have been diagnosed with SMM between 01 January 2016 and 31 December 2021. The study anticipates collecting data from at least 450 participants during a data collection period of approximately 12 months, at approximately 30 sites across 5 countries in Europe. This study primarily aims ...

GO TO STUDY